Appendix 4D, Half-year report of 30th June, 2019, has been lodged with the Australian Securities Exchange.
View Appendix 4D Half-year report.
Appendix 4D, Half-year report of 30 June, 2018
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.